CN107106664A - 用于调节淋巴细胞和治疗乙型肝炎病毒的ivig蛋白和kh蛋白的纯化组合物 - Google Patents

用于调节淋巴细胞和治疗乙型肝炎病毒的ivig蛋白和kh蛋白的纯化组合物 Download PDF

Info

Publication number
CN107106664A
CN107106664A CN201580041532.2A CN201580041532A CN107106664A CN 107106664 A CN107106664 A CN 107106664A CN 201580041532 A CN201580041532 A CN 201580041532A CN 107106664 A CN107106664 A CN 107106664A
Authority
CN
China
Prior art keywords
leu
glu
ser
lys
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580041532.2A
Other languages
English (en)
Chinese (zh)
Inventor
K·黄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
American Rare Antibody Antigen Supply Co
Original Assignee
American Rare Antibody Antigen Supply Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54699755&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN107106664(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by American Rare Antibody Antigen Supply Co filed Critical American Rare Antibody Antigen Supply Co
Publication of CN107106664A publication Critical patent/CN107106664A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201580041532.2A 2014-05-28 2015-05-28 用于调节淋巴细胞和治疗乙型肝炎病毒的ivig蛋白和kh蛋白的纯化组合物 Pending CN107106664A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462003664P 2014-05-28 2014-05-28
US62/003,664 2014-05-28
PCT/US2015/032807 WO2015184050A1 (en) 2014-05-28 2015-05-28 Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus

Publications (1)

Publication Number Publication Date
CN107106664A true CN107106664A (zh) 2017-08-29

Family

ID=54699755

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580041532.2A Pending CN107106664A (zh) 2014-05-28 2015-05-28 用于调节淋巴细胞和治疗乙型肝炎病毒的ivig蛋白和kh蛋白的纯化组合物

Country Status (10)

Country Link
EP (1) EP3148574B1 (https=)
JP (1) JP2017525752A (https=)
CN (1) CN107106664A (https=)
AU (1) AU2015266997A1 (https=)
BR (1) BR112016027818A2 (https=)
CA (1) CA2949994A1 (https=)
ES (1) ES2878043T3 (https=)
MX (1) MX2016015574A (https=)
RU (1) RU2016151761A (https=)
WO (1) WO2015184050A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118878610A (zh) * 2024-03-19 2024-11-01 北京达尔文细胞生物科技有限公司 一种蛋白聚合物及其生产工艺

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015184050A1 (en) 2014-05-28 2015-12-03 Rare Antibody Antigen Supply, Inc. Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus
US20160289300A1 (en) * 2015-04-02 2016-10-06 Kieu Hoang Method of manufacturing intravenous immunoglobulin from fraction iii
CN107921080A (zh) * 2015-04-02 2018-04-17 K·黄 由组分iii制造并纯化出用于静脉注射的凝血酶原复合物浓缩剂的方法以及治疗和预防具有抑制剂的a型血友病或感染了hiv‑1和hiv‑2的b型血友病患者的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1673368A (zh) * 2003-06-30 2005-09-28 弗·哈夫曼-拉罗切有限公司 Hcv调节的蛋白表达
CN102939304A (zh) * 2010-04-09 2013-02-20 诺维信生物制药丹麦公司 白蛋白衍生物和变体
TW201335371A (zh) * 2012-01-31 2013-09-01 Kieu Hoang Ａｆｏｄ及ａｆｃｃ之方法以及蛋白質之製備及純化方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3825429C2 (de) * 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
CA2639003A1 (en) 2008-08-20 2010-02-20 Canadian Blood Services Inhibition of fc.gamma.r-mediated phagocytosis with reduced immunoglobulin preparations
WO2011143637A1 (en) * 2010-05-14 2011-11-17 The Regents Of The University Of Colorado, A Body Corporate Improved complement receptor 2 (cr2) targeting groups
WO2015184050A1 (en) 2014-05-28 2015-12-03 Rare Antibody Antigen Supply, Inc. Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1673368A (zh) * 2003-06-30 2005-09-28 弗·哈夫曼-拉罗切有限公司 Hcv调节的蛋白表达
CN102939304A (zh) * 2010-04-09 2013-02-20 诺维信生物制药丹麦公司 白蛋白衍生物和变体
TW201335371A (zh) * 2012-01-31 2013-09-01 Kieu Hoang Ａｆｏｄ及ａｆｃｃ之方法以及蛋白質之製備及純化方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANGELI P等: "Nephrotoxicity of Intravenous Immunoglobulin in the Setting of Liver Transplantation or HBV-related Cirrhosis: An Undervalued Topic", 《MINERVA GASTROENTEROL DIETOL》 *
刘新民: "《中华医学百科大辞海 第1卷 内科学》", 31 July 2008, 军事医学科学出版社 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118878610A (zh) * 2024-03-19 2024-11-01 北京达尔文细胞生物科技有限公司 一种蛋白聚合物及其生产工艺

Also Published As

Publication number Publication date
ES2878043T3 (es) 2021-11-18
EP3148574A4 (en) 2017-04-05
MX2016015574A (es) 2018-05-28
RU2016151761A (ru) 2018-07-03
CA2949994A1 (en) 2015-12-03
WO2015184050A1 (en) 2015-12-03
EP3148574B1 (en) 2021-04-14
JP2017525752A (ja) 2017-09-07
AU2015266997A1 (en) 2016-12-08
BR112016027818A2 (pt) 2017-10-24
RU2016151761A3 (https=) 2018-12-26
EP3148574A1 (en) 2017-04-05

Similar Documents

Publication Publication Date Title
Raidt et al. Cellular events in the immune response: analysis and in vitro response of mouse spleen cell populations separated by differential flotation in albumin gradients
Raghavachar et al. T lymphocyte control of human eosinophilic granulopoiesis. Clonal analysis in an idiopathic hypereosinophilic syndrome.
DE69503903T2 (de) Positive und positive/negative zellselektion vermittelt durch peptiofreisetzung
EP3134120B1 (en) Compositions and methods for treating cytokine-related disorders
CN110974958B (zh) 一种抗pd-l1单克隆抗体的注射制剂
AU2007305076A1 (en) Immune modulators, preparations and compositions including immune modulators, tests for evaluating the activity of immune modulators and preparations and compositions including the same, and methods
CN107106664A (zh) 用于调节淋巴细胞和治疗乙型肝炎病毒的ivig蛋白和kh蛋白的纯化组合物
Lamon et al. The immune response to primary Moloney sarcoma virus tumors in BALB/c mice: cellular and humoral activity of long‐term regressors
US20180078581A1 (en) Exosomes Sourced from Granulocytic Myeloid-derived Suppressor Cells and Application thereof
WO2009148568A1 (en) Human facilitating cells
CN117886940B (zh) 人源化抗人cd132单克隆抗体及其应用
US5565338A (en) Suppressor T-cell hybridoma and production of allergen specific glycosylation inhibiting factor
US20200040063A1 (en) Process of cloning and further purification to make a recombinant intravenous immunoglobulin
WO2023046097A1 (zh) 抗tigit人源化抗体或其抗原结合片段及其应用
CN115287266A (zh) 一种靶向于猪RORγt的单克隆抗体及其杂交瘤细胞株和应用
DE3783511T2 (de) Verfahren zur zuechtung tierischer zellen und geeignete medien.
US20160289300A1 (en) Method of manufacturing intravenous immunoglobulin from fraction iii
DE68913793T2 (de) Ein von einem Human-Human-Hybridom abgeleiteter monoklonaler Antikörper und dessen Verwendung.
US20180021376A1 (en) Naming of KH1 through KH55 good healthy cells synthesizes the KH1 through KH55 proteins
JPS59116224A (ja) 免疫反応を抑制する組成物およびその製法
WO1986000927A1 (en) Antibody production
DE19728323A1 (de) Verwendung von BK-RiV-Präparaten und/oder ihren Bestandteilen in der Medizin und Veterinärmedizin zur Diagnose, Therapie und Prophylaxe, zur Prüfung und Normalisierung des "Allgemein zellulärsekretorischen Abwehrsystems" (AZSA) und der mit diesem kausal verknüpften Körperzustände
HK40083979A (en) Preparation method for universal car-t cells, and application thereof
CN101084923A (zh) 一种兔抗人t淋巴细胞免疫血清的制备方法
CN119923275A (zh) CD158d分子、其中和抗体，及应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170829